Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Cash & Equivalents (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Cash & Equivalents for 6 consecutive years, with $48.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 39.52% to $48.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $48.7 million, a 39.52% decrease, with the full-year FY2024 number at $69.8 million, up 21.56% from a year prior.
  • Cash & Equivalents was $48.7 million for Q3 2025 at Mereo BioPharma, down from $56.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $127.1 million in Q4 2021 to a low of $48.7 million in Q1 2024.
  • A 5-year average of $70.6 million and a median of $65.3 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 310.18% in 2021, then tumbled 46.36% in 2022.
  • Mereo BioPharma's Cash & Equivalents stood at $127.1 million in 2021, then crashed by 46.36% to $68.2 million in 2022, then fell by 15.78% to $57.4 million in 2023, then grew by 21.56% to $69.8 million in 2024, then plummeted by 30.23% to $48.7 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Cash & Equivalents are $48.7 million (Q3 2025), $56.1 million (Q2 2025), and $62.5 million (Q1 2025).